STOCK TITAN

Telesis Bio, Inc. - $TBIO STOCK NEWS

Welcome to our dedicated page for Telesis Bio news (Ticker: $TBIO), a resource for investors and traders seeking the latest updates and insights on Telesis Bio stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Telesis Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Telesis Bio's position in the market.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.35%
Tags
conferences
-
Rhea-AI Summary
Telesis Bio Inc. announces the closing of its private placement, raising $28.0 million in gross proceeds. The company may receive an additional $46.2 million if the warrants issued in the placement are cash exercised. Novalis LifeSciences LLC led the financing, with participation from other investors. Paul Meister from Novalis LifeSciences LLC joins the company's board of directors. The funds will be used for general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.35%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
none
-
Rhea-AI Summary
Telesis Bio Inc. will showcase their benchtop automation solutions for synthetic biology at SynBioBeta 2023. They will present in two speaker sessions and two poster sessions, focusing on the application of their BioXp platform for accelerating vaccine and biologics discovery workflows. The BioXp system provides a complete automated solution for optimizing the discovery process, enabling sequence to screening in days instead of weeks or months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.72%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.49%
Tags
conferences
-
Rhea-AI Summary
Telesis Bio Inc. reports total revenue of $6.3M in 1QFY23, with a 28% increase in BioXp franchise revenue. Gross margin improves to 55.6%. Operating expenses decrease to $14.5M. Net loss decreases to $11.1M. Cash and cash equivalents at $32.2M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.15%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.92%
Tags
conferences earnings
Telesis Bio, Inc.

Nasdaq:TBIO

TBIO Rankings

TBIO Stock Data

10.66M
9.26M
37.35%
38.22%
0.33%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
United States of America
SAN DIEGO

About TBIO

sgi-dna, a wholly owned subsidiary of synthetic genomics inc., provides genomic solutions to advance scientific discovery. sgi-dna’s ever expanding suite of products, services, reagents, bioinformatics tools and instrumentation enables scientists to discover, design and build novel solutions for basic research, as well as for biomedical and industrial applications. sgi-dna’s genomic services include whole genome sequencing, dna synthesis, library design, bioinformatics, cell engineering, and plasmid dna cloning and purification. sgi-dna’s reagents include a complete suite of gibson assembly® and site directed mutagenesis kits as well as optimized cell lines such as vmax™ a novel, fast growing host system for molecular biology. to further enable synthetic biology workflows, sgi-dna offers the bioxp™ 3200 system. this fully automated genomics workstation allows the creation of double stranded dna fragments, automated cloning, as well as next generation sequencing dna library preparation.